Inhaled Insulin Plus
Oral Hypoglycemics Effective Long-Term for Type 2 Diabetes
posted September 21, 2004
Exubera Reduced blood glucose levels
in patients with Type 2 diabetes, from an A1c of 9.6 to 7.7%.
An experimental inhaled insulin preparation called Exubera is effective in
controlling blood sugar levels in type 2 diabetics over prolonged periods of
time, the drug's developers said on Tuesday.
The results, presented at the Annual Meeting of the European Association for the
Study of Diabetes in Germany, showed that over 2 years Exubera reduced blood
glucose levels in patients with type II diabetes, with a fall in HbA1c levels
from 9.6% to 7.7%. HbA1c in patients in the control group, who took existing
drugs without Exubera, fell to 8.1%.
The two-year trial was designed to assess the efficacy of Exubera when added to
sulfonylurea or metformin. Some 304 patients completed the trial.
Pfizer Inc., which is developing the drug with Sanofi-Aventis and Nektar
Therapeutics, said both groups showed a slight reduction in lung function but
there was no significant difference between the two groups.
Concerns about reduced lung function have hampered progress of the product.
Safety concerns caused the companies to conduct additional clinical trials, and
delayed regulatory filing in the United States.
Source: Diabetes In Control.com.
September 2004
News Article Index